Parkinson’s disease
Roche advances treatment for Parkinson’s disease
June 16, 2025Research and Development Neurology, Parkinson's disease, Roche, clinical trials, neurodegenerative disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, an investigational therapy for Parkinson’s …
Abbvie acquires Cerevel Therapeutics
August 2, 2024Mergers and Acquisitions AbbVie, Cerevel Therapeutics, Drug-Resistant Epilepsy, Neurology, Parkinson's disease, major depressive disorder, mergers & acquisitions, neurology, neuroscience, schizophrenia
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple programmes across neurological and psychiatric …
AskBio initiates phase 2 Parkinson’s trial recruitment
June 26, 2024Research and Development AskBio, Neurology, Parkinson's disease, clinical trial
Asklepios BioPharmaceutical (AskBio), a subsidiary of Bayer, has announced that it has initiated the recruitment for its phase 2 REGENERATE-PD …
Nxera Pharma partner Neurocrine Biosciences enters phase 1 NBI-1117567 study
May 9, 2024Research and Development Alzheimer's disease, Neurocrine Biosciences, Neurology, Nxera Pharma, Parkinson's disease, clinical trials, dementia, schizophrenia
Nxera Pharma’s neuroscience-focused biopharmaceutical partner  Neurocrine Biosciences has announced it has successfully started its phase 1, first-in-human trial of investigational …
Amneal and Zambon Biotech enter agreement for Parkinson’s treatment
February 28, 2024Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement
Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …
Experimental drug could treat dyskinesia in people with Parkinson’s
March 2, 2020Sales and Marketing Parkinson's, Parkinson's disease, dyskinesia, spasms
Results from a new study researching treatment for dyskinesia has offered hope that it may be treatable in people with …
A new weapon against Parkinson’s-related psychosis
December 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, cannabidiol, cannabis, feature, pharma
Dr Arthur Roach, Director of Research at the charity Parkinson’s UK, discusses new trials on cannabidiol in the treatment of …
Scientists at King’s College London identify early signs of Parkinson’s disease
June 20, 2019Research and Development King's College London, Kings College London, Parkinson's disease, pharma, serotonin
Scientists at King’s College London say they have identified the earliest signs of Parkinson’s disease in the brain – 15 …
Parkinson’s disease: A quest for steadier therapies
June 7, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Parkinson's disease, biotech, drugs, pharma, pharmaceutical
The worrying number of deaths associated with Nuplazid has eyes returning to the pipeline for Parkinson’s disease. Anjali Shukla, a …
Asthma drugs reduce Parkinson’s risk by 50%, decade-long study finds
September 5, 2017Manufacturing and Production, Research and Development Parkinson's, Parkinson's disease, asthma, pharma, pharmaceuticals, salbutamol
A study from the Department of Global Public Health and Primary Care at the University of Bergen (UiB) in Norway …
Diabetes drug holds promise to slow Parkinson’s progression
August 4, 2017Medical Communications, Research and Development Parkinson's disease, biotech, diabetes, drugs, pharma, pharmaceutical
There are currently no treatments that are able to slow the development of Parkinson’s disease. This unmet medical need will …
Pfizer, IBM partner to develop monitoring system for Parkinson’s disease
April 8, 2016Medical Communications, Research and Development Parkinson's disease, Pfizer, collaboration, ibm, research, technology
US pharma giant Pfizer (NYSE: PFE) and International Business Machines Corp (NYSE: IBM) have partnered on a research project focussed on …
NHS England approves AbbVie’s Duodopa for Parkinson’s disease
July 6, 2015Sales and Marketing AbbVie, Duodopa, James Palmer, NHS England, PPRS, Parkinson's, Parkinson's disease, commissioning
AbbVie has been handed a boost by NHS England, who has approved the prescribing of its Parkinson’s disease treatment Duodopa …
UCB launches ‘Parkinson’s Well-Being Map’
April 13, 2012Medical Communications Parkinson's disease, UCB
UCB has launched a new visual tool to help people with Parkinson’s Disease to discuss their health and symptoms with …
GSK Parkinson’s drug shows motor skills benefits
August 16, 2011Research and Development GSK, Impax Pharmaceuticals, Parkinson's disease, research and development news
GlaxoSmithKline’s new drug IPX066 has helped Parkinson’s disease patients retain their motor skills after their medication wore off. IPX066, which …
